Allspring Global Investments Holdings LLC Reduces Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Chimerix, Inc. (NASDAQ:CMRXGet Rating) by 42.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 356,812 shares of the biopharmaceutical company’s stock after selling 266,856 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Chimerix were worth $688,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Chimerix during the second quarter worth approximately $30,000. Principal Financial Group Inc. lifted its holdings in shares of Chimerix by 77.1% during the 2nd quarter. Principal Financial Group Inc. now owns 20,007 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 8,710 shares in the last quarter. Walleye Trading LLC acquired a new position in shares of Chimerix during the 2nd quarter valued at $45,000. Engineers Gate Manager LP acquired a new position in shares of Chimerix during the 1st quarter valued at $54,000. Finally, Ergoteles LLC acquired a new position in shares of Chimerix during the 1st quarter valued at $65,000. 58.03% of the stock is owned by hedge funds and other institutional investors.

Chimerix Stock Performance

CMRX opened at $1.83 on Monday. The company has a 50-day moving average of $2.02 and a 200-day moving average of $2.08. The company has a market capitalization of $161.12 million, a P/E ratio of 1.05 and a beta of 1.17. Chimerix, Inc. has a 1-year low of $1.27 and a 1-year high of $6.43.

Chimerix (NASDAQ:CMRXGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.10 by $0.65. Chimerix had a net margin of 464.75% and a return on equity of 147.04%. The business had revenue of $32.56 million during the quarter, compared to the consensus estimate of $205.30 million. As a group, sell-side analysts expect that Chimerix, Inc. will post 1.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Chimerix from a “hold” rating to a “buy” rating in a research note on Friday, November 4th. Four investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $8.50.

About Chimerix

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Featured Articles

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRXGet Rating).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.